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Summary European clinical trials of zonisamide as adjunctive therapy for refrac-
tory partial seizures included a 12-week double-blind, placebo-controlled study and
a 15-month open-label extension study. In the double-blind study, patients (n = 144)
were randomized to placebo or zonisamide (400mg QD) after baseline evaluation. Pa-
tients completing the double-bind study (n= 115) continued on open-label zonisamide
for up to 18 months. Median percent reduction in partial seizures from baseline
was signiﬁcantly greater in zonisamide-treated patients compared to those receiving
placebo (31.6% versus 3.3%, respectively; P = 0.008). Additionally, more zonisamide-
treated patients achieved ≥50% reduction in seizure frequency relative to base-
line than did placebo patients (30.4% versus 14.7%, respectively; P = 0.03). The
extension study showed that zonisamide efﬁcacy was maintained or improved over
time. Patient and physician assessments favored zonisamide over placebo in terms of
patient improvement with treatment. Median zonisamide maintenance dosage was
400mg/day, and the average therapeutic blood level was 16.9g/mL. Both stud-
ies showed that zonisamide was well tolerated; adverse events were generally mild
to moderate and most frequently included fatigue, dizziness, somnolence, and
anorexia.
Collectively, these ﬁndings corroborate those of US and Asian clinical trials, which
also show that zonisamide is safe and effective for adjunctive therapy of partial
seizures.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Zonisamide (Zonegran®), a sulfonamide analogue
with broad-spectrum anticonvulsant activity,1 has
been prescribed in Japan and Korea for 15 and 12
years, respectively, and recently received regula-
tory approval in the United States and Europe. The
development of zonisamide for the European mar-
ket began in May 1984 with clinical trials sponsored
by Warner—Lambert; currently, zonisamide devel-
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opment is continuing under the sponsorship of Eisai
Inc.
The European trial was conducted in two phases:
it began with a double-blind, placebo-controlled
study, and was followed by an open-label exten-
sion in which all patients received long-term zon-
isamide treatment. The primary objective of these
studies was to evaluate the efﬁcacy and safety of
zonisamide as an adjunctive therapy for patients
with refractory partial seizures. Another objec-
tive was to determine the dose and plasma levels
of zonisamide associated with signiﬁcant seizure
reduction.
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Table 1 Demographic and baseline seizure proﬁle.
Demographic characteristic Zonisamide (n = 73) Placebo (n = 71)
Gender (%)
Male 43 (59) 42 (59)
Female 30 (41) 29 (41)
Race (%)
Caucasian 73 (100) 71 (100)
Age (years, mean ± S.D.) 35 ± 11 34 ± 12
Weight (kg, mean ± S.D.) 67 ± 11 66 ± 10
Height (cm, mean ± S.D.) 168 ± 8 168 ± 10
Monthly seizures, median (range)
All partial 11.3 (2.5—763) 11.0 (2.8—435)
Complex partial 10.0 (2.5—763) 10.0 (2.8—217)
Other (including generalized) 0 (0—5) 0 (0—4.5)
Method
Placebo-controlled study
A total of 144 patients at 10 sites were randomized
to treatment with zonisamide or placebo (Table 1).
Patients were included in the study if they were be-
tween 18 and 59 years of age, had a history of re-
fractory partial seizures (at least four seizures per
month in the previous 4 months), and were being
treated with one or two antiepilepsy drugs (AEDs),
but not more than two of the following: phenytoin,
carbamazepine, sodium valproate, phenobarbital,
or primidone. In addition, patients had to be capa-
ble of counting the number of seizures that they ex-
perienced, because their record of seizure activity
was an important component of the study data. Pa-
tients who had progressive central nervous system
disease, more than eight generalized tonic-clonic
seizures while awake during the 4 months prior to
the study, signiﬁcant mental retardation, a history
of drug or alcohol abuse, or abnormal laboratory
values unrelated to AED therapy were not eligi-
ble for participation in the study. Results from 9 of
the 10 centers have been published previously by
Schmidt et al.2
Baseline seizure data were recorded daily for the
ﬁrst 8 weeks of the study (Table 1 and Fig. 1). Dur-
ing this baseline period, patients continued to take
previously prescribed AEDs. Patients who recorded
at least 30 seizures during this baseline period
proceeded directly to the treatment introduction
phase; those who had fewer than 30 seizures dur-
ing this time continued recording seizure activity
for an additional 4 weeks before the treatment
introduction phase was begun.
Following the baseline period, each patient
was randomly assigned to receive zonisamide or
placebo, in addition to their other AEDs, for 12
weeks (Fig. 1). Treatment was introduced over
a titration period of 4 weeks, during which zon-
isamide dosing began at 100mg/day for the ﬁrst
week, increased to 200mg/day for the second
week, and to 400mg/day for the third and fourth
weeks. Zonisamide was administered orally as cap-
sules containing 100mg of the drug; placebo also
was titrated from one to four capsules per day.
After titration, zonisamide doses were measured
using a high-performance liquid chromatography
(HPLC) method, and adjusted by a nonblinded ob-
server to achieve a blood level of 20—30g/mL,
a range that had been shown in previous studies
to be a level associated with high efﬁcacy.3,4 The
nonblinded observer also ensured that zonisamide
doses did not exceed 20mg/kg per day and that
zonisamide plasma levels did not exceed 40g/mL.
Random adjustments were made in the number of
placebo capsules to maintain the study blind. All
Figure 1 Schematic diagram of double-blind and
open-label zonisamide clinical trials.
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patients continued at the adjusted dosage levels
for 8 weeks beyond the titration period. Postran-
domization seizure data were not obtainable from
seven patients; thus, data analyzed were for an
intent-to-treat population consisting of 137 pa-
tients.
Efﬁcacy measures included median change from
baseline in seizure frequency, and the percentage
of treatment responders over the full-dose, 8-week
treatment period. A treatment responder was de-
ﬁned as any patient who achieved a≥50% reduction
in seizure frequency relative to baseline. Additional
efﬁcacy measures included physician and patient
global assessments, made either at the completion
of the 12-week double-blind treatment period, or at
the time of withdrawal from the study. Each patient
and physician independently rated the changes in
the patient’s condition with treatment as markedly
improved, slightly improved, unchanged, or worse.
Safety was assessed based on the frequency and
severity of adverse events, as well as on results
from laboratory tests (hematology, chemistry,
and urinalysis) and electroencephalogram (EEG)
evaluations.
Open-label study
Patients who completed the double-blind study
were eligible to enroll in an open-label extension
study to examine the long-term safety and efﬁ-
cacy of zonisamide. A total of 115 patients from 10
centers entered the open-label study. Fifty-three
of these patients had received zonisamide during
the double-blind study and continued at the same
dose throughout the open-label study for a total
mean duration of therapy of 445 days (median dose
of 500mg/day). The 62 patients who had received
Figure 2 Comparison of zonisamide (black bars) and placebo (gray bars) treatment on efﬁcacy endpoints for patients
in the double-blind study. Efﬁcacy endpoints were the median percentage seizure reduction from baseline (a), and
the percentage of patients with ≥50% seizure reduction from baseline (b), for all partial seizures, complex partial
seizures, and all seizures. Statistical comparisons were made using a two-way analysis of variance (ANOVA) test using
treatment and site as factors.
placebo began taking zonisamide at doses titrated
over a 4-week period to 400—600mg/day; they
remained at this dose for a total mean duration
of 321 days. Zonisamide doses could be adjusted
based on investigators’ clinical judgment, provided
that daily dosage did not exceed 20mg/kg per day
or an amount producing zonisamide plasma levels
of 40g/mL.
For the open-label study, efﬁcacy measures were
percent reduction in seizure frequency relative to
baseline and response rate. Safety was assessed
in terms of the frequency and severity of adverse
events.
Results
Placebo-controlled study: efﬁcacy
ﬁndings
As shown in Fig. 2, in the placebo-controlled study,
zonisamide treatment produced a signiﬁcant reduc-
tion in seizure activity for all partial seizures, com-
plex partial seizures, and all seizures (partial and
generalized). Zonisamide treatment also produced
a signiﬁcant increase in the percentage of patients
who were considered responders for all partial
seizures and all seizures. A strong trend toward an
increased response rate for complex partial seizures
(P = 0.055) was also observed in patients treated
with zonisamide. Furthermore, both physician
and patient global assessments indicated a signiﬁ-
cantly greater level of improvement than was seen
with placebo (Fig. 3). Although the median dose
of zonisamide given to responders was the same
as nonresponders (400mg/day), weight-adjusted
doses were somewhat lower among nonresponders
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Figure 3 Patients and physicians individually assessed
the patient’s improvement during the treatment phase
(weeks 5—12) of the double-blind study. Evaluations were
scored as marked improvement (dark gray bar), slight
improvement (light gray bar), no change (black bar), or
worse (empty bar). Statistical comparisons were made
using the Cochran—Mantel—Haenszel test stratiﬁed by
center.
(Table 2). Among responders, 16 patients received
between 400 and 600mg/day, and the remaining
patient received a dose of 200mg/day (data not
shown). Median plasma levels of zonisamide were
16.9 and 13.0g/mL for responders and nonrespon-
ders, respectively. Therapeutic dosage and plasma
levels for zonisamide observed in this study are
within the ranges of those reported elsewhere.1,3—5
Other AEDs taken by patients in this study were
carbamazepine, phenytoin, sodium valproate,
primidone, and phenobarbital. Blood levels of all
concomitant AEDs were nearly identical before
and after zonisamide treatment (Fig. 4).2 These
results suggest that zonisamide does not affect
the metabolism of these concomitant AEDs, and
Table 2 Zonisamide dosage and plasma levels:
placebo-controlled study.
Final dosage Plasma level
(g/mL)
mg/day mg/kg per day
Respondersa (n = 17)
Median 400 7.4 16.9
Range 200—600 3.3—9.3 3.8—30.7
Nonrespondersa (n = 52)
Median 400 6.2 13.0
Range 100—1000 1.7—15.6 2.6—35.0
a Subgroups of the zonisamide treatment group
(n = 73).
that the efﬁcacy of zonisamide is not secondary to
changes in the levels of concomitant AEDs.
Safety ﬁndings
Adverse events that occurred with the use of zon-
isamide were considered mild or moderate in sever-
ity, and are similar to those encountered with other
AEDs. Overall, 45 (62%) patients receiving zon-
isamide, and 22 (31%) patients given the placebo,
reported one or more treatment-emergent adverse
event(s). The most frequent adverse events (those
occurring in ≥10% of patients) were fatigue, dizzi-
ness, somnolence, anorexia, ataxia, and trouble
concentrating (Table 3). The frequency of dizzi-
ness, anorexia, ataxia, and trouble concentrat-
ing were signiﬁcantly increased among patients
treated with zonisamide relative to those treated
with placebo suggesting that these adverse events
were attributable to the addition of zonisamide
treatment to other AEDs. No clear relationship was
observed between zonisamide plasma levels and
frequency or type of adverse events.
Five of the patients treated with zonisamide,
and one patient treated with placebo, with-
drew from the double-blind study because of ad-
verse events. Those events experienced by the
zonisamide-treated patients were nervousness, fa-
tigue, drowsiness, difﬁculty concentrating, memory
problems, and headache; the patient who received
placebo reported fatigue, difﬁculty concentrating,
apathy, and hair loss.
Laboratory tests (hematology, chemistry, urinal-
ysis) showed no changes of clinical consequence.
EEG evaluations showed changes expected of pa-
tients with refractory seizures. Seventeen patients
treated with zonisamide, and 14 patients treated
with placebo, showed signiﬁcant changes in labora-
Table 3 Most frequent adverse events: placebo-
controlled study.
Adverse
events (≥10%)
Zonisamide
(n = 73)
Placebo
(n = 71)
n % n %
Fatigue 17 23.3 8 11.3
Dizziness 12 16.4a 3 4.2
Somnolence 11 15.1 6 8.5
Anorexia 9 12.3a 1 1.4
Ataxia 9 12.3a 0 0.0
Trouble
concentrating
9 12.3a 1 1.4
a Statistically different from placebo (P≤ 0.05 Fisher’s
exact test).
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Figure 4 Plasma concentration of concomitant AEDs. Blood levels for concomitant AEDs were measured during the
baseline period and after add-on zonisamide treatment. Data from Schmidt et al.2
tory values between treatment and baseline peri-
ods.
Results
Open-label study: efﬁcacy ﬁndings
Of the 115 patients who began the open-label study,
32 (28%) patients were treated with zonisamide for
more than 15 months, and 52 (45%) patients were
treated for at least 12 months. Because of missing
baseline data for four patients, the efﬁcacy analysis
included 111 patients. The median percent reduc-
tion from baseline in seizure frequency was 45.4%
for all partial seizures and 47.0% for complex par-
tial seizures. Between 33 and 55% of all patients
were responders (experiencing a ≥50% reduction in
seizure frequency) for all seizure categories, de-
pending on the time interval assessed (months 4—6,
7—9, 10—12, 13—15, ≥15). In addition, comparison
of response rates from the placebo-controlled study
with those from the extension study shows that the
efﬁcacy of zonisamide was maintained over time.
Safety ﬁndings
The most frequent adverse events observed with
long-term zonisamide treatment were fatigue (23%
in the original zonisamide group versus 16% in
the previous placebo group), somnolence (9% ver-
sus 21%), trouble concentrating (11% versus 16%),
anorexia (9% versus 14%), and depression (4% ver-
sus 9%). All adverse events were characterized as
mild or moderate, and only 18.3% of all adverse
events were considered by study investigators to
be related to zonisamide treatment. Nineteen pa-
tients (16.5%) withdrew from the study as a result
of adverse events. Two patients experienced se-
rious or potentially serious adverse events during
this study, including carcinoma and renal calculi. A
third patient died. The cause of death was unre-
lated to the study drug.
Discussions and conclusions
These studies demonstrate that zonisamide is a safe
and effective adjunctive treatment for epilepsy.
Zonisamide was well tolerated during short- and
long-term treatment. In addition, the lack of any
effect of zonisamide on concomitant AED levels
favors its use in polytherapy. These conclusions are
in agreement with those from clinical trials con-
ducted with zonisamide in Japan and the United
States, and from extensive postmarketing experi-
ence in Japan and Korea.
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